Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/13677
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTantitamit T.
dc.contributor.authorHuang K.-G.
dc.contributor.authorManopunya M.
dc.contributor.authorYen C.-F.
dc.date.accessioned2021-04-05T03:25:35Z-
dc.date.available2021-04-05T03:25:35Z-
dc.date.issued2018
dc.identifier.issn22133070
dc.identifier.other2-s2.0-85046877592
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/13677-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85046877592&doi=10.4103%2fGMIT.GMIT-10-18&partnerID=40&md5=e5fa66474d0b28e75483a2e6337dabeb
dc.description.abstractUterine leiomyosarcoma (uLMS) is a rare and aggressive cancer, usually diagnosed incidentally at the time of myomectomy or hysterectomy. There have been concerns for several years about the fact that the inadvertent disruption of occult uLMS may have a negative impact on patient outcome. This study reviews the outcome and management of patients with a diagnosis of uLMS after surgery for presumed benign disease. We conducted a literature search in which 47 published English-language articles were obtained for evaluation. A total of 23 studies with outcomes data were included. It is evidenced that patients who underwent surgery with tumor disruption resulted in poorer outcomes compared with en bloc tumor, especially by power morcellation. The power morcellation was associated with an increased risk of recurrence, shorten time to recurrence, and upstage after re-exploration. Early re-exploration and surgical staging are appreciated for better prognosis and may alter postoperative treatment. We also updated on the incidence and preoperative evaluation to assess the risk of patient and give an effective counseling. © 2018 Gynecology and Minimally Invasive Therapy | Published by Wolters Kluwer - Medknow.
dc.subjectCA 125 antigen
dc.subjectfluorodeoxyglucose
dc.subjectabdominal hysterectomy
dc.subjectantibody blood level
dc.subjectcancer prognosis
dc.subjectcancer risk
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectclinical effectiveness
dc.subjectcolor Doppler flowmetry
dc.subjectconservative treatment
dc.subjectdisease marker
dc.subjectechography
dc.subjectfemale
dc.subjectfemale fertility
dc.subjecthuman
dc.subjectincidence
dc.subjectleiomyosarcoma
dc.subjectmyomectomy
dc.subjectnuclear magnetic resonance imaging
dc.subjectoutcome assessment
dc.subjectpeak systolic velocity
dc.subjectpositron emission tomography
dc.subjectpreoperative evaluation
dc.subjectpriority journal
dc.subjectrecurrence risk
dc.subjectreproductive success
dc.subjectReview
dc.subjectrisk factor
dc.subjectsalpingooophorectomy
dc.subjectsurvival rate
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjecttumor volume
dc.subjectultrasound
dc.subjectuterine leiomyosarcoma
dc.subjectuterus disease
dc.subjectuterus sarcoma
dc.subjectuterus weight
dc.titleOutcome and management of uterine leiomyosarcoma treated following surgery for presumed benign disease: Review of literature
dc.typeReview
dc.rights.holderScopus
dc.identifier.bibliograpycitationGynecology and Minimally Invasive Therapy. Vol 7, No.2 (2018), p.47-55
dc.identifier.doi10.4103/GMIT.GMIT-10-18
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.